A case of Stevens-Johnson Syndrome (SJS) induced by carbamazepine in a psychiatric patient with schizo-affective disorder is reported. The patient also had diabetes mellitus and was on glyburide which posed an initial dilemma at the onset of SJS as to the causative drug. In view of the expanding use of carbamazepine in psychiatric patients and the potentially lethal consequences of SJS, the authors suggest a risk management approach when initiating Carbamazepine therapy to reduce the incidence and morbidity of the syndrome.
Coleman, Albert M.D., M.P.H. and Trappler, B. M.D.
"Stevens-Johnson Syndrome Following Treatment With Carbamazepine for a Mood Disorder,"
Jefferson Journal of Psychiatry:
1, Article 8.
Available at: http://jdc.jefferson.edu/jeffjpsychiatry/vol13/iss1/8